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Enhanced expression of vascular endothelial
growth factor in lungs of newborn infants with
congenital diaphragmatic hernia and pulmonary
hypertension
Sherif M K Shehata, Wolter J Mooi, Tadaharu Okazaki, Ibrahim El-Banna, Hari S Sharma,
Dick Tibboel
Abstract
Background—Pulmonary hypoplasia ac-
companied by pulmonary hypertension
resistant to treatment is an important fea-
ture of congenital diaphragmatic hernia
(CDH). The pathogenesis of the pulmo-
nary vascular abnormalities in CDH re-
mains to be elucidated at the molecular
level. Vascular endothelial growth factor
(VEGF), an endothelial cell specific mi-
togen, is known to play a role in pulmo-
nary angiogenesis and vascular
remodelling but there are no data on
VEGF expression in patients with CDH.
Methods—Necroscopic lung specimens
from 21 patients with CDH with lung
hypoplasia and from seven age matched
control newborn infants without lung
hypoplasia were processed for immuno-
histochemical analysis using aYnity puri-
fied anti-human VEGF antibodies. All the
cases of CDH had pulmonary hypoplasia,
indicated by a lung/body weight index of
<0.012, and pulmonary hypertension in-
dicated by repeated cardiac ultrasonogra-
phy. Cellular localisation of VEGF was
semiquantitatively analysed using a stain-
ing score ranging from 0 (no staining) to 4
(very strong staining).
Results—Significantly raised levels of
VEGF immunoreactivity were observed
in lung specimens from cases of CDH
compared with controls. VEGF was de-
tected mainly in the bronchial epithelium
and the medial smooth muscle cells of
large (>200 µm) and small (<200 µm) pul-
monary arteries, the most intense stain-
ing being in the medial smooth muscle
cells of the small pulmonary arteries.
Endothelial cells were positive for VEGF
staining in patients with CDH but not in
controls.
Conclusions—This is the first study of
VEGF expression in newborn infants with
CDH. Increased levels of VEGF, especially
in the small, pressure regulating pulmo-
nary arteries, point to a potential role in
vascular remodelling. This may reflect an
unsuccessful attempt by the developing
fetus to increase the pulmonary vascular
bed in the hypoplastic lungs to alleviate
the associated pulmonary hypertension.
(Thorax 1999;54:427–431)
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Congenital diaphragmatic hernia (CDH) re-
mains one of the major challenges in paediatric
surgery and neonatology. Despite recent devel-
opments in therapeutic modalities such as
delayed surgery, exogenous surfactant therapy,
nitric oxide (NO) inhalation, extracorporeal
membrane oxygenation (ECMO), and partial
liquid ventilation, the mortality rate remains
around 40% in high risk cases.1–3 The main
pathological findings reported in the lungs of
infants with CDH are lung hypoplasia and pul-
monary vascular abnormalities including (a)
reduced total pulmonary vascular bed and
decreased number of vessels per volume unit of
lung and (b) medial hyperplasia of pulmonary
arteries together with peripheral extension of
the muscle layer into small arterioles.4–6 The
most common cause of the unfavourable
outcome in human CDH is persistent pulmo-
nary hypertension.2–5 Indeed, follow up of sur-
viving patients with CDH has revealed that the
pulmonary perfusion scan does not improve
although the ventilation scan improves towards
nearly normal levels.7
A recent developmental study of the lung
vasculature showed that in early gestation the
pulmonary vasculature develops by a combina-
tion of central angiogenic sprouting and the
formation of peripheral vasculogenic lakes
which progressively communicate with each
other as gestation advances.8 A number of
growth factors with a proven or potential role
in vascular development and remodelling in
health and disease conditions have been
identified.9 10 Vascular endothelial growth fac-
tor (VEGF), a potent angiogenic growth
factor, has been reported to have a narrow tar-
get cell specificity to endothelial cells. More-
over, VEGF regulates vasculogenesis and post-
natal vascular remodelling.11–13 VEGF binds to
high aYnity cell surface receptors, KDR/flk
and flt, which are predominantly expressed in
endothelial cells.13 Expression of VEGF is
upregulated under a variety of pathophysi-
ological conditions including pulmonary
hypoxia.12–14
In order to investigate the pathogenesis
of the underlying vascular abnormalities in
CDH lungs we have investigated the cellular
localisation of VEGF in pulmonary necropsy
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specimens obtained from neonates with CDH
and age matched controls.
Methods
TISSUE SPECIMENS
Lung tissue specimens used in this study were
obtained from our archival collection at the
Department of Pathology. These specimens
represent material from 21 patients with CDH
treated at Sophia Children’s Hospital during
the period 1981–97 who had died and from
whom necroscopic material was obtained with
the parents’ consent. All cases were associated
with lung hypoplasia, as indicated by a
lung/body weight ratio index of <0.012.15 The
control group consisted of seven age matched
neonates who had died in the first 24 hours of
extrauterine life because of neonatal asphyxia
or placental insuYciency. These control cases
did not have lung hypoplasia on histological
screening. The CDH group had a gestational
age varying from 35 weeks to term, with a mean
of 38.4 weeks, while that of the control group
was 35.1 weeks. Neither the CDH nor the con-
trol group was subjected to ECMO treatment.
The left or right lung was chosen randomly for
examination since no significant diVerences
were found between the two lungs on histologi-
cal screening in subjects with CDH.
Lung tissue specimens were fixed in formalin
by immersion fixation and embedded in paraf-
fin for histopathological examination and
immunohistochemical analysis.
IMMUNOHISTOCHEMICAL ANALYSIS
ParaYn sections (6 µm thickness) of the lung
tissues were cut and mounted on glass slides
coated with 3-amino-propyl-trioxysilane
(Sigma, St Louis, MO, USA). Immunohisto-
chemical analysis was performed using a
standard avidin-biotin complex (ABC) method
as described previously.16 17 In brief, after
deparaYnisation in xylene and rehydration
through graded alcohol, the slides were rinsed
with water and phosphate buVered saline
(PBS) and placed in a Sequeza Immunostain-
ing Workstation (Shandon Scientific Ltd,
Astmoor, Runcorn, UK). The slides were pre-
incubated for 15 minutes with normal goat
serum to block non-specific binding, then
incubated for 30 minutes at room temperature
with aYnity purified rabbit polyclonal antibod-
ies in a dilution of 1:200. The anti-VEGF
antiserum used was raised against a 20 amino
acid synthetic peptide corresponding to resi-
dues 1–20 of the amino terminus of human
VEGF18 (Santa Cruz Biotechnology Inc, Santa
Cruz, USA).
The optimal dilution was identified by
examining the intensity of staining obtained
with a series of dilutions of the antiserum from
1:50 to 1:500. The dilution (1:200) resulted in
specific and easily visible signals in paraYn
sections of a capillary haemangioma.The haem-
angioma sections served as a positive control in
the study. After washing with PBS, the test and
control slides were incubated for 30 minutes
with biotinylated secondary antibody (Multi-
link, 1:75 dilution, Biogenex, San Ramon, MO,
USA). After two washes in PBS the slides were
incubated for 30 minutes with alkaline phos-
phatase conjugated streptavidin (Biogenex) in
a dilution of 1:50, then rinsed with 0.2 M Tris
HCl, pH 8.0. Levamisole (Sigma) was used to
block the endogenous alkaline phosphatase
activity and the slides were stained for 30 min-
utes with 0.3% new fuchsin/Tris HCl (Sigma)
for colour enhancement. Negative controls
were prepared by omission of the primary
antiserum. The slides were lightly counter-
stained with Mayer’s haematoxylin for 10
seconds.
Immunolocalisation of VEGF in endothelial
cells and smooth muscle cells was verified by
staining with specific markers. Endothelial cells
were identified by CD31 immunostaining.19
Staining was performed by the ABC method
using 0.025% 3,3-diaminobenzidine (DAB) as
chromogen. The slides were incubated for 20
minutes in methanol with 0.3% H2O2 to block
the endogenous peroxidase activity. They were
then incubated with the primary anti-human
CD31 monoclonal antibody in a dilution of
1:80 (Dako Corporation, Glostrup, Denmark)
at room temperature for 30 minutes and
subsequently visualised after developing the
colour with 0.025% DAB. Using the DAB
based colour development method, consecu-
tive tissue sections were stained with anti-
human mouse monoclonal á-smooth muscle
actin (áSMA) antibody (clone 1A4, Biogenex)
in a dilution of 1:200.
SEMIQUANTITATIVE ANALYSIS
Prior to screening, sections were coded so that
the observers were unaware of the clinical
details of the case under study. VEGF expres-
sion was analysed semiquantitatively using a
visual scale ranging from 0 to 4 (grade 0 = no
staining, grade 1 = focal staining, grade 2 =
diVuse faint staining, grade 3 = diVuse moder-
ate staining, and grade 4 = diVuse strong
staining).20 The entire slide of a tissue block
taken from the mid lung area was investigated
and scored at the same magnification by three
independent observers and the average used
for subsequent analysis. Sections were graded
0–4 for the localisation of VEGF in the
bronchial epithelium, endothelium, and medial
smooth muscle cells in small (50–200 µm
external diameter) and large (>200 µm exter-
nal diameter) pulmonary arteries.21 This scor-
ing method has previously been shown to allow
the detection of diVerences in expression levels
as small as 1.5 times.20 22
STATISTICAL ANALYSIS
The median VEGF staining score was calcu-
lated for the two groups. Before ranking, the
scores were rounded to the nearest complete
number. Statistical analysis was performed
after ranking using either the Mann–Whitney
test or Fisher’s exact test as appropriate. A p
value of <0.05 was considered significant.
Results
CLINICAL AND NECROPSY DATA
Thirteen of the 21 diaphragmatic hernias were
left sided. All patients presented in the first six
hours of life and were treated according to a
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standard protocol including conventional me-
chanical ventilation, cardiac ultrasound, and
delayed surgery.1 Clinical evidence of right to
left shunting was obtained by preductal and
postductal transcutaneous oxygen saturation
diVerences of >10% in cases of CDH.23 Echo-
cardiography documented the right to left
shunt and pulmonary hypertension. In three
cases associated major congenital anomalies
were found (Fallot’s tetralogy, tracheo-
oesophageal cleft, and trisomy 21, respec-
tively). Nineteen of the neonates with CDH
died within 48 hours of birth, five in the first
hour. In three instances hyaline membrane dis-
ease was observed and one patient developed
pulmonary bleeding. All seven age matched
controls had died in the first 24 hours after
birth. Control cases were subjected to ventila-
tory therapy in settings similar to those of the
CDH cases, including inspiratory oxygen frac-
tion of 1.0 for variable periods up to 16 hours
postnatally.
LOCALISATION OF VEGF
VEGF was found in the bronchial epithelium
and medial arterial smooth muscle cells of the
control cases. Distinct VEGF immunostaining
was identified in the bronchial epithelium and
the medial smooth muscle cells of the pulmo-
nary arteries in tissue specimens from the
CDH group, as verified by immunolocalisaton
of áSMA. VEGF immunoreactivity in the
bronchial epithelium and arterial medial
smooth muscle cells was more intense in the
CDH cases than in the controls (fig 1A and B).
In the CDH group VEGF staining in the
pulmonary vasculature was most intense in the
medial smooth muscle cells of the small
pulmonary arteries with an external diameter
of <200 µm. High levels of VEGF expression
were also found in the supernumerary arteries
from the CDH cases. VEGF expression was
detected in the endothelium of the pulmonary
arteries only in the CDH cases (fig 1C). This
endothelial staining was colocalised using con-
secutive sections stained with the endothelial
cell marker CD31 (fig 1D). No VEGF immu-
nopositivity was detected in the endothelium of
controls (fig 1B). Weak VEGF expression was
observed in the medial smooth muscle cells of
large pulmonary veins in the CDH cases.
No diVerences in the pattern of VEGF
expression were seen between the CDH cases
artificially ventilated for up to 48 hours and the
five cases who died in the first hour after birth
despite maximal attempted resuscitation, even
without receiving vigorous ventilatory support.
No VEGF expression was observed in the arte-
rial medial smooth muscle cells of pulmonary
veins in the control group.
The mean VEGF expression score in the
CDH cases had a maximal value of 3.38 in the
bronchial epithelial cells. Endothelial and
medial smooth muscle cells of large pulmonary
arteries (external diameter >200 µm) had low
staining values of 0.5 and 1.43, respectively.
Statistical analysis of the VEGF expression
scores in the two groups showed significantly
higher levels (p<0.05) in the bronchial epithe-
lium and medial smooth muscle cells of the
large and small pulmonary arteries of the CDH
group compared with controls (p = 0.001,
0.027, and 0.002, respectively, using the
non-parametric Mann-Whitney U test, table
1).
Figure 1 Immunohistochemical localisation of VEGF in lung tissue. (A) Intense expression of VEGF in the medial
smooth muscle cells of small diameter pulmonary arteries and in the bronchial epithelium of CDH lung tissue. (B)
Expression of VEGF in the bronchial epithelium and faintly in the smooth muscle cells of the pulmonary arteries of control
non-hypoplastic lung tissue. (C) Expression of VEGF in the arterial endothelium (arrowed) and medial smooth muscle
cells of pulmonary arteries in CDH hypoplastic lung tissue. (D) Arterial endothelium identified (arrow) by CD31 staining
using peroxidase technique. (Calibration bars = 50 µm in A and B and 25 µm in C and D).
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Since there was no expression of VEGF in
the endothelium of the pulmonary arteries in
the controls and the score was always zero,
Fisher’s exact test was considered more appro-
priate for the comparison of endothelial
staining scores.24 25 Significantly higher expres-
sion was observed in the endothelial cells of
CDH cases using Fisher’s exact test with p
values of 0.01 and <0.001 for large and small
pulmonary arteries, respectively, compared
with controls.
Discussion
We have found increased VEGF immunoreac-
tivity in the endothelium and medial smooth
muscle cells of pulmonary arteries in cases of
CDH with pulmonary hypoplasia. The highest
levels of expression in the pulmonary vascula-
ture were observed in the medial smooth mus-
cle cells of arteries with a diameter of less than
200 µm, particularly in the supernumerary
arteries which are known to play an important
role in pulmonary blood pressure regulation
and vascular resistance.26
Our results are in agreement with a previous
experimental report which confirmed that the
arterial medial smooth muscle cells are a
source of VEGF.27 The increased VEGF
expression detected in CDH cannot be due to
artificial ventilation since we did not find any
diVerence in VEGF expression between the
patients ventilated for short (up to one hour) or
longer (up to 48 hours) periods. In addition, no
diVerences in the degree of VEGF expression
were found in bronchial epithelium in the
CDH group, regardless of whether or not these
lungs were exposed to high levels of inspiratory
oxygen or volume trauma and shear forces
related to variable periods of artificial ventila-
tion.
Since no significant diVerences in lung
hypoplasia have been reported between the
right and left lungs from infants with high risk
CDH,28 29 we randomly chose either lung from
the CDH group for study. In agreement with
previous studies, we found no diVerences
between the lungs in a preliminary examina-
tion.
VEGF is recognised as an endothelial cell
mitogen and angiogenic inducer with activity
restricted to the vascular endothelial cells.30 31 It
is expressed in a variety of cells and a paracrine
mechanism of action has been suggested
whereby non-endothelial cells secrete VEGF
which modulates the vasculogenesis and angio-
genesis in the adjacent vascular endothelium.27
This important angiogenic role of VEGF is
indicated by the fact that abnormal vessel
development leading to death occurred in
embryos lacking a single VEGF allele32 or
following the experimental inactivation of the
VEGF gene by replacing the coding sequence
of exon 3 of the VEGF gene in embryonic stem
cells.33
We found endothelial reactivity for VEGF in
the pulmonary vasculature of human CDH
hypoplastic lungs but not in the control cases;
this is in agreement with a previous study
which reported that VEGF is not expressed in
the normal endothelium of the developing
fetus.27 However, it has previously been re-
ported that, in endothelial cells derived from
microvessels, VEGF expression can be upregu-
lated in vitro by hypoxia and adenosine.34 35
There is a similarity between the structural
changes in the pulmonary vasculature of CDH
hypoplastic lungs and that of another paediat-
ric form of pulmonary hypertension—namely,
persistent pulmonary hypertension of
neonates.9 36 It is unclear whether similar
growth factors and cytokines contribute to
these vascular abnormalities.37 Furthermore, it
is of note that increased VEGF expression has
been reported in the lungs of patients with pri-
mary pulmonary hypertension.37
Our knowledge of vascular development in
congenital diaphragmatic hernia and/or vascu-
lar remodelling following postnatal interven-
tions is far from complete, and it is too early to
speculate in detail about the pulmonary vascu-
lar abnormalities at the molecular level. There
is no doubt that growth factors play an essential
role in the development and maturation of the
pulmonary and vascular systems.38 39 The
increased VEGF expression in small diameter
and supernumerary pulmonary arteries in
CDH cases complicated by pulmonary hyper-
tension may reflect an apparently unsuccessful
attempt by the developing fetus and neonate to
compensate for the stunted lung vessel growth
and/or to stimulate arterial angiogenesis of the
pulmonary pressure regulating arteries caused
by a mechanism which remains to be identi-
fied.
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